CN112638904A - 2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-腈的固体形式 - Google Patents
2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-腈的固体形式 Download PDFInfo
- Publication number
- CN112638904A CN112638904A CN201980056826.0A CN201980056826A CN112638904A CN 112638904 A CN112638904 A CN 112638904A CN 201980056826 A CN201980056826 A CN 201980056826A CN 112638904 A CN112638904 A CN 112638904A
- Authority
- CN
- China
- Prior art keywords
- diffraction pattern
- crystalline form
- ray powder
- powder diffraction
- crystalline
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Inorganic Chemistry (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862692914P | 2018-07-02 | 2018-07-02 | |
| US62/692,914 | 2018-07-02 | ||
| PCT/US2019/040276 WO2020010068A1 (en) | 2018-07-02 | 2019-07-02 | Solid forms of 2-(3,5-dichloro-4-((5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yl)oxy)phenyl)-3,5-dioxo-2,3,4,5-tetrahydro-1,2,4-triazine-6-carbonitrile |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN112638904A true CN112638904A (zh) | 2021-04-09 |
Family
ID=67441642
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980056826.0A Pending CN112638904A (zh) | 2018-07-02 | 2019-07-02 | 2-(3,5-二氯-4-((5-异丙基-6-氧代-1,6-二氢哒嗪-3-基)氧基)苯基)-3,5-二氧代-2,3,4,5-四氢-1,2,4-三嗪-6-腈的固体形式 |
Country Status (12)
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114787153A (zh) * | 2019-12-26 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| WO2026067708A1 (zh) * | 2024-09-30 | 2026-04-02 | 齐鲁制药有限公司 | 瑞司美替罗晶型及其制备方法和用途 |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2795450T3 (es) | 2012-09-17 | 2020-11-23 | Madrigal Pharmaceuticals Inc | Procedimiento para sintetizar análogos de hormonas tiroideas y polimorfos de los mismos |
| MX394463B (es) | 2016-10-18 | 2025-03-19 | Madrigal Pharmaceuticals Inc | Métodos para tratar trastornos del hígado o trastornos lipídicos con un agonista de thr-beta. |
| CN119431265A (zh) | 2019-02-21 | 2025-02-14 | 南京瑞捷医药科技有限公司 | 一种作为甲状腺激素受体激动剂的化合物 |
| WO2020227549A1 (en) | 2019-05-08 | 2020-11-12 | Aligos Therapeutics, Inc. | MODULATORS OF THR-β AND METHODS OF USE THEREOF |
| WO2021063367A1 (zh) * | 2019-09-30 | 2021-04-08 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| KR20230066408A (ko) | 2020-09-10 | 2023-05-15 | 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. | 레스메티롬의 결정형, 이의 제조 방법 및 이의 용도 |
| US12616701B2 (en) | 2020-10-19 | 2026-05-05 | Assia Chemical Industries Ltd | Solid state forms of Resmetirom |
| WO2022165227A1 (en) * | 2021-02-01 | 2022-08-04 | Madrigal Pharmaceuticals, Inc. | Therapeutic combinations of rosuvastatin and resmetirom for the treatment of liver disorders or lipid disorders |
| CN114907327A (zh) * | 2021-02-10 | 2022-08-16 | 杭州领业医药科技有限公司 | Resmetirom的晶型及其制备方法和用途 |
| US20240218009A1 (en) * | 2021-04-21 | 2024-07-04 | Merck Sharp & Dohme Llc | Novel forms of cyclic dinucleotide compounds |
| TW202337470A (zh) | 2021-09-27 | 2023-10-01 | 美商瑪德瑞高製藥公司 | 用於縮減肝臟體積之瑞美替隆 |
| MX2024005647A (es) * | 2021-11-11 | 2024-05-24 | Terns Pharmaceuticals Inc | Tratamiento de trastornos hepaticos con un agonista del thr-\03b2. |
| JP2026521649A (ja) | 2023-06-22 | 2026-06-30 | マドリガル ファーマシューティカルズ インコーポレイテッド | THR-βアゴニストを用いて肝障害を治療するためのバイオマーカーおよび関連する使用 |
| EP4762048A2 (en) | 2023-10-16 | 2026-06-24 | Cipla Limited | Resmetirom polymorphs and process for their preparation |
| WO2025171032A1 (en) | 2024-02-06 | 2025-08-14 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| US12377104B1 (en) | 2024-02-06 | 2025-08-05 | Madrigal Pharmaceuticals, Inc. | Methods for treating a fatty liver disease |
| WO2025172958A1 (en) * | 2024-02-16 | 2025-08-21 | Metrochem Api Pvt Ltd | Solid state forms of resmetirom |
| WO2025231587A1 (zh) * | 2024-05-06 | 2025-11-13 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗无水晶型ch及其制备方法 |
| WO2026074443A1 (en) | 2024-10-01 | 2026-04-09 | Assia Chemical Industries Ltd. | Solid state forms of resmetirom |
| WO2026107045A1 (en) | 2024-11-12 | 2026-05-21 | Madrigal Pharmaceuticals, Inc. | Resmetirom for use in treating cardiomyopathy and/or related heart failure and portal hypertension |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101228135A (zh) * | 2005-07-21 | 2008-07-23 | 霍夫曼-拉罗奇有限公司 | 作为甲状腺激素受体激动剂的哒嗪酮衍生物 |
| CN105008335A (zh) * | 2012-09-17 | 2015-10-28 | 马德里加尔制药公司 | 合成甲状腺激素类似物及其多形体的方法 |
| WO2018075650A1 (en) * | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL150524A0 (en) * | 2000-01-07 | 2003-02-12 | Transform Pharmaceuticals Inc | High-throughput formation, identification, and analysis of diverse solid-forms |
| US12616701B2 (en) * | 2020-10-19 | 2026-05-05 | Assia Chemical Industries Ltd | Solid state forms of Resmetirom |
-
2019
- 2019-07-01 TW TW114125593A patent/TW202615431A/zh unknown
- 2019-07-01 TW TW108123112A patent/TW202019914A/zh unknown
- 2019-07-01 AR ARP190101846A patent/AR115666A1/es unknown
- 2019-07-02 MX MX2021000107A patent/MX2021000107A/es unknown
- 2019-07-02 EP EP19745399.6A patent/EP3818057A1/en not_active Withdrawn
- 2019-07-02 IL IL321116A patent/IL321116A/en unknown
- 2019-07-02 US US17/257,070 patent/US20210122740A1/en not_active Abandoned
- 2019-07-02 KR KR1020257038532A patent/KR20250167140A/ko not_active Ceased
- 2019-07-02 WO PCT/US2019/040276 patent/WO2020010068A1/en not_active Ceased
- 2019-07-02 KR KR1020217003360A patent/KR102890565B1/ko active Active
- 2019-07-02 JP JP2020572517A patent/JP2021530456A/ja active Pending
- 2019-07-02 EP EP24214548.0A patent/EP4552643A3/en active Pending
- 2019-07-02 CA CA3104860A patent/CA3104860A1/en active Pending
- 2019-07-02 AU AU2019298236A patent/AU2019298236A1/en not_active Abandoned
- 2019-07-02 CN CN201980056826.0A patent/CN112638904A/zh active Pending
-
2020
- 2020-12-23 IL IL279700A patent/IL279700A/en unknown
-
2021
- 2021-01-06 MX MX2023009701A patent/MX2023009701A/es unknown
- 2021-01-06 MX MX2024013198A patent/MX2024013198A/es unknown
-
2024
- 2024-05-09 JP JP2024076310A patent/JP2024105460A/ja active Pending
- 2024-11-15 US US18/949,309 patent/US20250074898A1/en active Pending
-
2025
- 2025-01-10 AU AU2025200189A patent/AU2025200189A1/en active Pending
- 2025-08-19 US US19/303,585 patent/US20250368626A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101228135A (zh) * | 2005-07-21 | 2008-07-23 | 霍夫曼-拉罗奇有限公司 | 作为甲状腺激素受体激动剂的哒嗪酮衍生物 |
| CN105008335A (zh) * | 2012-09-17 | 2015-10-28 | 马德里加尔制药公司 | 合成甲状腺激素类似物及其多形体的方法 |
| WO2018075650A1 (en) * | 2016-10-18 | 2018-04-26 | Madrigal Pharmaceuticals, Inc. | Methods of treating liver disorders or lipid disorders with a thr-beta agonist |
Non-Patent Citations (4)
| Title |
|---|
| ABU T. M. SERAJUDDIN等: "Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises,Subsequent Problems, and Recent Breakthroughs" * |
| MARTHA J. KELLY等: "Discovery of 2‑[3,5-Dichloro-4-(5-isopropyl-6-oxo-1,6-dihydropyridazin-3-yloxy)phenyl]-3,5-dioxo-2,3,4,5-tetrahydro[1,2,4]triazine-6-carbonitrile (MGL-3196), a Highly Selective Thyroid Hormone Receptor β Agonist in Clinical Trials for the Treatment of Dyslipidemia" * |
| MINO R. CAIRA等: "Crystalline Polymorphism of Organic Compounds" * |
| ROLF HILFIKER等: "Relevance of Solid-state Properties for Pharmaceutical Products" * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114787153A (zh) * | 2019-12-26 | 2022-07-22 | 苏州科睿思制药有限公司 | 一种Resmetirom晶型及其制备方法和用途 |
| WO2025011259A1 (zh) * | 2023-07-07 | 2025-01-16 | 苏州科睿思制药有限公司 | 瑞司美替罗的晶型及其制备方法和用途 |
| CN119613386A (zh) * | 2023-09-14 | 2025-03-14 | 杭州科巢生物科技有限公司 | 一种瑞司美替罗1,4-二氧六环溶剂化合物及其制备方法 |
| WO2026067708A1 (zh) * | 2024-09-30 | 2026-04-02 | 齐鲁制药有限公司 | 瑞司美替罗晶型及其制备方法和用途 |
Also Published As
| Publication number | Publication date |
|---|---|
| US20250368626A1 (en) | 2025-12-04 |
| US20210122740A1 (en) | 2021-04-29 |
| EP3818057A1 (en) | 2021-05-12 |
| EP4552643A3 (en) | 2025-07-02 |
| WO2020010068A1 (en) | 2020-01-09 |
| AU2019298236A1 (en) | 2021-01-21 |
| KR20210027454A (ko) | 2021-03-10 |
| KR20250167140A (ko) | 2025-11-28 |
| US20250074898A1 (en) | 2025-03-06 |
| TW202615431A (zh) | 2026-04-16 |
| CA3104860A1 (en) | 2020-01-09 |
| AU2025200189A1 (en) | 2025-01-30 |
| EP4552643A2 (en) | 2025-05-14 |
| AR115666A1 (es) | 2021-02-10 |
| IL321116A (en) | 2025-07-01 |
| MX2024013198A (es) | 2024-12-06 |
| KR102890565B1 (ko) | 2025-11-24 |
| MX2021000107A (es) | 2021-05-27 |
| IL279700A (en) | 2021-03-01 |
| TW202019914A (zh) | 2020-06-01 |
| JP2021530456A (ja) | 2021-11-11 |
| JP2024105460A (ja) | 2024-08-06 |
| MX2023009701A (es) | 2023-08-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102890565B1 (ko) | 2-(3,5-디클로로-4-((5-이소프로필-6-옥소-1,6-디히드로피리다진-3-일)옥시)페닐)-3,5-디옥소-2,3,4,5-테트라히드로-1,2,4-트리아진-6-카르보니트릴의 고체 형태 | |
| US20250388550A1 (en) | Salts of an antioxidant and crystalline forms thereof | |
| AU2025200217A1 (en) | Systems and methods for preparing tailored radioactive isotope solutions | |
| JP2021512910A (ja) | ノボビオシン類似体とプロリンとの共結晶形態 | |
| CN111918859B (zh) | 稠合三环γ-氨基酸衍生物的盐的晶型及制备和应用 | |
| US8946474B2 (en) | Polymorphic form of a calcimimetic compound | |
| JP2024038059A (ja) | 4-フェニルチアゾール誘導体の結晶形およびその調製方法 | |
| US11136332B2 (en) | Morphic forms of marizomib and uses thereof | |
| EP4444720A1 (en) | Rabeximod compounds | |
| EP3941588A1 (en) | Co-crystal forms of selinexor | |
| US9056814B2 (en) | Polymorphic form of a calcimimetic compound | |
| HK40119275A (en) | Co-crystal forms of a novobiocin analog and proline | |
| JP7517705B2 (ja) | フロピリミジン化合物の塩および結晶形ならびにその医薬用途 | |
| CN112384221A (zh) | 异喹啉酮的多晶态和非晶态形式及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20210409 |
|
| WD01 | Invention patent application deemed withdrawn after publication |